TruthArchive.ai - Related Video Feed

The speaker asks if the Pfizer COVID vaccine was tested for its ability to stop virus transmission before being released. They request a clear yes or no answer and the data to be shared with the committee. The response states that they did not have prior knowledge of stopping transmission before the vaccine entered the market and had to rely on scientific research. Another speaker expresses outrage, claiming that people were pressured to get vaccinated based on the false belief that it would protect others.

The speakers argue about the approval and payment terms of the Pfizer vaccine in the US. Speaker 0 claims that the vaccine was approved months before, while Speaker 1 disagrees. Speaker 1 admits to not having read the full contract but argues that the payment made was for an advanced purchase agreement. Speaker 0 disputes this, stating that there is no advanced payment clause in the contract. Speaker 2 clarifies that the payment was made to guarantee Canadian access to doses from Medicago.

The speaker asked if the Pfizer COVID vaccine was tested for stopping virus transmission before it was released. They wanted a clear yes or no answer and requested the data to be shared with the committee. In response, it was stated that no, they did not have knowledge about stopping transmission before the vaccine entered the market. They had to act quickly.

Speaker 0 is hesitant about getting the vaccine, but Speaker 2 explains that getting vaccinated protects others. Speaker 3 is skeptical due to the quick vaccine development. Speaker 1 emphasizes the importance of vaccination to stop the virus spread. Speaker 3 believes there is fear-mongering around the pandemic.

People in America are hesitant to get vaccinated due to the lack of clear information and the speed at which the vaccine was developed. However, one person points out that it used to take years to develop vaccines, but now it can be done in a shorter time frame. Another person argues that nine months is not enough time to trust a vaccine that was created so quickly. The importance of vaccination is emphasized, as it can help stop the spread of the virus. The comparison is made between COVID-19 and the flu, with COVID-19 being seen as more serious due to the higher number of deaths. The conversation ends with one person expressing skepticism about the incentives and fear tactics used to promote vaccination.

Speaker 0 questions understanding of vaccine causing myocarditis, mentioning Pfizer's awareness. Speaker 1 doubts if vaccine was tested for stopping transmission before market release. Speaker 0 believes vaccination was optional, not forced.

Thank you, Senator Canavan. Did Pfizer test if the COVID-19 vaccine could stop or reduce virus transmission before its late 2020 approval? To bring the vaccine to patients, we needed to show it was safe and effective in preventing illness, severe disease, and hospitalizations. The primary goal was to protect the vaccinated individual. I appreciate that, but my question remains unanswered. On December 3, 2020, your CEO stated that it was uncertain if vaccinated individuals could carry and spread the virus. Was he correct that Pfizer did not know if the vaccine could reduce transmission? We designed our clinical programs with regulatory agencies to demonstrate the vaccine's safety and effectiveness in preventing infections. Okay, let’s move on.

Speaker 1 expresses skepticism about the COVID-19 vaccine due to lack of clarity and the speed at which it was developed. Speaker 2 counters by explaining that 20 years of scientific research contributed to its creation. Speaker 0, who is vaccinated, argues that if more people refuse the vaccine, the virus will continue to spread. Speaker 1 questions the accuracy of COVID-19 death numbers and suggests ulterior motives behind vaccine incentives. Speaker 0 emphasizes the importance of protecting health and the city. Speaker 1 accuses the pandemic of being fear-driven.

Speaker 0 and Speaker 1 discuss the importance of getting vaccinated to protect family members. Speaker 2 is hesitant due to lack of clarity and the quick development of the vaccine. Speaker 1 explains the extensive scientific research behind the vaccine. Speaker 0 emphasizes the need for vaccination to stop the virus from spreading. Speaker 2 expresses concerns about fear tactics and incentives for vaccination. The conversation highlights the importance of vaccination in preventing the spread of COVID-19.

In a meeting on October 6, 2021, questions arose about the ethics of administering experimental booster shots and whether financial motives influenced their rollout. The discussion highlighted that while mRNA vaccines have been researched for decades, they had not previously reached clinical trials due to known side effects. Pfizer and Moderna utilized the pandemic's emergency status to expedite their vaccines. A collaboration with BioNTech, initiated before COVID-19, led to the development of mRNA technology. The urgency of the pandemic required rapid action, leaving little time for thorough deliberation. Katherine Janssen, a key figure in vaccine development at Pfizer, emphasized the ongoing efforts to create effective vaccines against COVID-19.

I spoke with Pfizer's CEO, Albert Bourla, about the approval process. We discussed vaccine safety and serious side effects. Many companies and institutions are embracing the COVID vaccine due to its effectiveness. Logistics are crucial in this process. Translation (if needed): I talked to Pfizer's CEO, Albert Bourla, about the approval process. We talked about vaccine safety and serious side effects. Many companies and institutions are adopting the COVID vaccine because it works well. Logistics are important in this situation.

Pfizer was asked if they tested whether their COVID-19 vaccine could reduce or stop the transmission of the virus before its approval. The Pfizer representative stated that the primary purpose of the vaccine was to protect the person who received it and prevent illness, severe disease, and hospitalizations. The senator then referred to a statement made by Pfizer's CEO on December 3, 2020, where he mentioned uncertainty about the vaccine's ability to reduce transmission. The Pfizer representative reiterated that their clinical programs were designed to demonstrate the vaccine's safety and effectiveness in preventing infections. Due to time constraints, the senator moved on without a definitive answer.

The speakers discuss the importance of vaccination in reducing transmission and returning to normalcy. They express confidence in the vaccines' ability to prevent illness and transmission. They emphasize the need for people to get vaccinated for their own protection and to break the chain of transmission. Vaccinated individuals are seen as dead ends for the virus, preventing further spread. However, it is mentioned that initial data on vaccine effectiveness against transmission was limited at the time of emergency use authorization. A question is raised about whether the Pfizer vaccine was tested for transmission prevention before its release, to which the response is that they had to move quickly based on scientific progress.

The transcript describes a contentious exchange about the COVID-19 vaccine and the roles of public health figures and political leaders. Key points include: - Speaker 0 asserts there was a “fake vaccine” pushed by Antony Fauci and Deborah Birx, accusing Trump of failing to fire them and allowing them to “destroy the said economy,” impose “fascist restrictions,” and promote a vaccine that Speaker 0 claims has “killed and maimed breathtaking numbers of people.” The vaccine is described as self-replicating and not proven safe or effective, with the period framed as Trump’s Christmas message in 2020 during Operation Warp Speed. - Speaker 1 counters that millions of doses of a safe and effective vaccine were delivered, thanking scientists, researchers, manufacturing workers, and service members, calling it a “Christmas miracle.” - Speaker 0 then reframes Trump’s stance, labeling the vaccine push as aligned with the agendas of Gates, Fauci, Klaus Schwab, and the World Economic Forum, calling them “the deep state” and asserting that Trump was pushing their agenda rather than opposing it. - A year later, in late 2021, Speaker 0 notes ongoing consequences of the vaccine and the pandemic, while Speaker 1 repeats positive messaging about the vaccine’s safety and effectiveness, and asserts that those who do not take the vaccine may experience more severe illness if they become very sick and go to the hospital. Speaker 1 emphasizes that the vaccine “worked” and that taking it provides protection, while non-vaccination is framed as a personal choice. - In the ensuing exchange, Speaker 1 makes a historical analogy, claiming the vaccine is “one of the greatest achievements of mankind,” noting that during the Spanish flu there were no vaccines, and claiming three vaccines were developed in less than nine months, whereas it would normally take five to twelve years. - Speaker 2 interjects, noting that more people died under Biden than under Trump during the year being discussed, and that more people took the vaccine that year, prompting a defense from Speaker 1 that the vaccine is effective and reduces the severity of illness, while if one contracts COVID, the illness is minor with vaccination. - The sequence ends with Speaker 0 labeling what was said as “utter, utter mendacity” and “Lying.” Overall, the transcript centers on a polarized debate over the vaccine’s safety and efficacy, the motivations and actions of public health officials and political leaders, contrasting claims that the vaccine was a dangerous, coerced plot with claims that it was a safe, efficacious public health breakthrough. It also juxtaposes Trump’s mixed public positions from 2020–2021, ranging from criticism of the vaccine push to praise of the vaccine as a major achievement.

Speaker 0 acknowledges reports of myocarditis and pericarditis associated with the Pfizer vaccine but seems unsure about the mechanism behind it. Speaker 1 asks if the vaccine was tested for its ability to stop virus transmission before being released. Speaker 2 questions if people were forced to get vaccinated to keep their jobs and asks Speaker 0 to retract their statement. Speaker 0 clarifies that everyone had the choice to get vaccinated or not, and they don't believe anyone was forced.

Speaker 0 and Speaker 1 discuss the COVID-19 vaccine episode, challenging why the vaccine was pursued as a public health solution and exploring deeper incentives behind the program. - A knowledgeable figure at the stand answered a burning question: did they know the vaccine wouldn’t be effective from the start and could be dangerous? The answer given was that it was “a test of a technology.” The exchange suggests the broader aim was testing an entire program of control previewed in Event 2019. - They ask whether inoculation was necessary on billions, noting it could have been tested on a much smaller population. If shots had been basically empty or inert, the data could have been spun to claim success and end the pandemic, preventing injuries from appearing. The absence of that approach remains a mystery. - The speakers point to high pre-vaccine seroprevalence in 2020, including studies from South Dakota showing 50-60% seroprevalence before vaccine release, implying that a saline shot or no shot could have achieved “indomicity” (immunity) without a vaccine. - They discuss why people might fear vaccines and interpret the broader impact: the public is waking up to something terrible having occurred, as it revealed readiness to lie, potential data quality concerns, and risk to pregnant women and healthy children who might get little justification for risk. - The disease’s lethality is framed as greatest among the very old or very sick; for others, it was less deadly, with natural evolution potentially reducing vulnerability over time. - The mRNA platform was touted as a means to outrun mutations, but the timeline to release was still insufficient to stay ahead of natural change. They note accelerated development was the fastest vaccine in history, from detection to inoculation, reducing the timeline by about a year or two, yet not fast enough. - Political and logistical factors delayed release; there is mention that it would not have appeared under Trump and that Eric Topol argued to delay the rollout. Fauci reportedly sent Moderna back to trials due to insufficient racial diversity in participants. - The discussion questions whether the vaccine qualifies as a normal consumer product, given ongoing subsidies, mandates, indemnifications, wartime-like supports, and propaganda. They wonder if there has been an ongoing two-century revolt by industry against public scrutiny, with public interest repeatedly leading to pushback and rebranding. - A central theme is the sophistication of pharma: the “game of pharma” involves owning an IP-based health claim, crafting supportive research, convincing it is safe and effective, achieving standard-of-care status, securing mandates and government funding, and leveraging ongoing propaganda. They describe pharma as a long-running arms race with deep institutional knowledge, implying that it is far more capable of shaping reality than the public realizes.

The Pfizer COVID vaccine was not tested for its ability to stop the transmission of the virus before it entered the market. The speaker acknowledges that they had to work quickly to understand the situation and move at the speed of science.

The speaker discusses the decision-making process for the COVID vaccine, highlighting the role of Operation Warp Speed and the lack of FDA involvement. They praise the collaboration between NIH and FDA, emphasizing the dedication of the team. The speaker commends the public-private partnership and the effectiveness of Operation Warp Speed. They express a wish for earlier financial support from the government for the industry.

Speaker 0 asks Speaker 1 to explain why the vaccine causes myocarditis and pericarditis. Speaker 1 mentions rare reports of myocarditis and pericarditis associated with vaccination but does not provide a clear explanation. Speaker 0 insists on understanding the mechanism and questions why the vaccine is considered safe without addressing the risks. Speaker 2 intervenes, suggesting that Speaker 1 will address the question later. Speaker 1 talks about the benefit-risk ratio and the global recommendation of health authorities. Speaker 0 reiterates the question, to which Speaker 1 agrees to provide a response later. Speaker 2 confirms this agreement.

Speaker 0 reassures that the situation isn't that bad and emphasizes the importance of proven protection against COVID. Speaker 1 and Speaker 2 discuss the need for everyone to get vaccinated to combat the virus. They mention the speed of vaccine development and the importance of avoiding misinformation. Speaker 0 highlights the effectiveness of vaccines and Speaker 2 explains the process of getting vaccinated for free through registration. They express their eagerness to keep their community safe and encourage others to get vaccinated. The transcript ends with Speaker 1 eagerly requesting to receive the vaccine.

Speaker 0 questions Speaker 1 about a report stating that serious adverse reactions occur in 1 in 800 vaccinated individuals. Speaker 1 claims to be unaware of the report but mentions routine screening of literature for adverse events. When asked about Moderna's rate of serious adverse events, Speaker 1 cannot provide the information. Speaker 0 expresses frustration and finds it extraordinary that a multinational company cannot provide this data. Speaker 1 offers to provide the information later but states that no safety concerns were observed in their clinical trials. Speaker 0 concludes that the conversation is a waste of time.

The speaker asked if the Pfizer COVID vaccine was tested for stopping virus transmission before it was released. They requested a clear yes or no answer and asked for the data to be shared with the committee. The speaker then stated that they did not have knowledge about stopping immunization before the vaccine entered the market.

Speaker 0 asked about the visibility of the medium to long-term effects of the vaccine in three to five years. Speaker 1 responded that they cannot predict how things will be in three to five years, but mentioned that 92-93% of the population will be vaccinated. Speaker 0 expressed confusion, and Speaker 1 clarified that 92-93% is the current vaccination rate. Speaker 0 raised concerns about potential side effects, but Speaker 1 reassured them that if there are any, the majority of the population would be affected. Speaker 0 remained unconvinced and expressed hesitation about getting vaccinated.

Pfizer representatives appeared before the Senate Committee to address questions about their COVID-19 vaccine. The committee asked if Pfizer tested whether the vaccine could reduce virus transmission before its approval. Pfizer stated that their clinical trials focused on demonstrating the vaccine's safety and effectiveness in preventing illness, severe disease, and hospitalizations. The committee also questioned Pfizer's statements regarding the vaccine's ability to stop transmission. Pfizer representatives were unable to provide specific evidence for these claims and agreed to provide further information to the committee. The committee expressed concern about the discrepancy between Pfizer's statements and requested clarification on any updated statements from Pfizer officials.